BioPlus Specialty Pharmacy Dispensing Non-opioid Pain Medication Qutenza® (Capsaicin) 8% Patch in Exclusive Relationship

BioPlus Specialty Pharmacy Dispensing Non-opioid Pain Medication Qutenza® (Capsaicin) 8% Patch in Exclusive Relationship


BioPlus Specialty Pharmacy, one of the nation’s leading innovative specialty pharmacies, announces an exclusive partnership to dispense 
Qutenza for post-shingles pain.

BioPlus Specialty Pharmacy, one of the nation’s leading innovative specialty pharmacies, announces an exclusive partnership to dispense Qutenza for post-shingles pain. 

BioPlus Specialty Pharmacy (BioPlus), a leading innovative specialty pharmacy, announces an exclusive relationship to dispense the prescription-strength non- opioid pain medication Qutenza® (capsaicin) 8% patch from Averitas Pharma, Inc. Qutenza (capsaicin) 8% patch is indicated for the management of neuropathic pain associated with postherpetic neuralgia, also known as post-shingles pain. The most common side effects of Qutenza are application site redness, application site pain, application site itching, small bumps where Qutenza is applied, and nausea. 

Qutenza is a topical treatment in the form of a patch providing 8% capsaicin and is the first and only prescription-strength capsaicin product for treating post-shingles pain. A single, one-hour treatment can provide up to three months of pain relief from post-shingles pain. The treatment can be repeated every three months, if needed. 

“After a bout of shingles, patients can develop a very painful neuralgia that can interfere and limit enjoying daily activities. Qutenza is an option for long-lasting pain relief for these patients and BioPlus is pleased to provide exclusive access to dispensing this treatment option,” shares Sharon Ferrer, VP of Pharmaceutical Relations at BioPlus. 

“Pain relief is not far away, since BioPlus ensures prompt treatment starts with our 2-Day Ready 2 Ship program that quickly gets medications to patients,” adds David DuRoss, Senior Vice President of Trade for BioPlus. 

Qutenza has been FDA approved since 2009 for the safe and effective management of post-shingles pain, which can feel like a constant intense burning or stabbing pain. Averitas Pharma acquired the US rights to Qutenza late last year. 

“By partnering with BioPlus as the exclusive specialty pharmacy for Qutenza, healthcare professionals and patients will have a single-point of contact for benefit verification services, ordering Qutenza patches and arranging for treatment so patients can benefit from pain relief,” explains Doug Stefanelli, President of Averitas Pharma. “Qutenza isn’t right for everyone and must be applied by a healthcare professional. However, if Qutenza can benefit a patient, we want to make sure that the customer experience is efficient.” 

 

Share this article

Share on facebook
Share on twitter
Share on linkedin
Share on email
Scroll to Top